Linzatin D Tablet contains Dapagliflozin 10mg + Linagliptin 5mg, a dual-action oral antidiabetic therapy for type 2 diabetes. Dapagliflozin, an SGLT2 inhibitor, promotes renal glucose excretion, while Linagliptin, a DPP-4 inhibitor, enhances incretin activity to stimulate insulin release and suppress glucagon secretion.
This tablet belongs to the diabetes care segment, offering a complementary mechanism for optimal blood glucose management. Its fixed-dose combination reduces pill burden and supports better adherence in patients needing multiple therapeutic actions.
Linzatin D Tablet is widely prescribed by endocrinologists, general physicians, hospitals, and clinics, making it a high-demand product for PCD pharma franchise and B2B distribution. Its dual mechanism ensures effective glycemic control, encouraging repeat prescriptions and patient satisfaction.
For PCD pharma franchise and B2B partners, Linzatin D Tablet represents a profitable and high-demand opportunity. With strong demand in hospitals, clinics, and retail pharmacies, it is ideal for domestic distribution, export, and third-party manufacturing, ensuring sustainable business growth and attractive margins.